Recently, a study showed that the frequency of PD-1+CD8+ T cells relative to PD-1+ regulatory T cells or Tregs in the TME is a far superior biomarker that can predict the efficacy of anti-PD-1 treatments than PD-L1 expression and tumor mutation burden (223). The gene discussed is CD274; the disease is neoplasm.